Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14205
Abstract: In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non-small cell lung carcinoma harboring mesenchymal-epithelial transition (MET) exon 14 skipping… read more here.
Keywords: intolerable peripheral; capmatinib successfully; peripheral edema; edema ... See more keywords